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Identity 
Other names: PHLPPL; KIAA0931 




The gene for PHLPP2 is located at 16q22.3 and spans 
approximately 70 kb. The most recent version of the 
Ensembl database predicts four splice variants of 
PHLPP2, whose sizes range from 69.8 to 73.9 kb (see 
diagram). 
Transcription 
The predicted PHLPP2 transcripts have between 2877 
and 7919 bp. Three of these predicted variants have18 
exons; the 7718 bp variant has only 17 exons. All of the 
variants have similar exon structures; only exon 1 and  
 
 
exon 7 (which is missing in the 7718 bp variant) differ.  
Of these putative transcripts, only the largest of hese 
transcripts (labeled "PHLPP2" in the diagram) has been 
cloned and characterized. 
Protein 
Description 
Like the related isoform PHLPP1beta, the PHLPP2 
protein contains a Ras association (RA) domain, a 
pleckstrin homology (PH) domain, a series of leucine-
rich repeats (LRR), a PP2C phosphatase domain, and a 
C-terminal PDZ (post synaptic density protein 
[PSD95], Drosophila disc large tumor suppressor 
[DlgA], and zonula occludens-1 protein [zo-1]) bindi g 
motif. The characterized PHLPP1 protein has 1323 
amino acids and a predicted molecular weight of 
approximately 147 kDa. Of the uncharacterized shorter 
transcripts, the longer (1256 aa) variant has a similar 
structure, while the two shorter variants (792 and 956
amino acids respectively) lack the RA and PH domains. 
 
Genomic organization of the PHLPP2 transcripts. Exons are represented by boxes, and position along chromosome 16 is indicated by 
the scale bar at the top. 
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PHLPP2 protein structure. 
 
Expression 
PHLPP2 is expressed in many human cancer cell lines
and in all mouse tissues examined so far. 
Localisation 
PHLPP2 appears to be predominantly expressed in the 
cytosolic and nuclear fractions. 
Function 
PHLPP2, like PHLPP1, dephosphorylates Akt and 
conventional/novel protein kinase C (PKC) isoforms at 
their hydrophobic motifs (HM). Both kinases are 
regulated by phosphorylation at this site, which 
corresponds to serine 473 in Akt1 and serine 660 in 
PKCbetaII. HM motif phosphorylation of Akt occurs 
under agonist-stimulated conditions and allows full 
activation of the kinase. Phosphorylation of PKC's HM
motif, on the other hand, is constitutive and regulates 
PKC stability. HM dephosphorylation by PHLPP 
renders PKC susceptible to dephosphorylation at two 
other important regulatory sites on the kinase (the 
activation loop and the turn motif). The fully-
dephosphorylated form of PKC is shunted to the 
detergent-insoluble pellet and degraded. Thus, PHLPP 
functions to decrease Akt's activity and PKC's stabili y, 
effectively dowregulating both kinases. 
While PHLPP2 and its family member PHLPP1 have 
similar functions, their specificity for Akt isoforms 
differs. PHLPP1 preferentially binds and 
dephosphorylates Akt2 and Akt3, resulting in 
decreased phosphorylation of a set of Akt targets that
includes GSK-3beta, TSC2, and FoxO, as well as 
HDM2 and GSK3a. PHLPP2, on the other hand, binds 
and dephosphorylates Akt1 and Akt3, resulting in 
downregulation of an overlapping yet distinct set of 
downstream targets: GSK-3beta, TSC2, and FoxO, as 
well as TSC2 and p27. 
PHLPP2 regulates cellular survival and proliferation, 
partially by regulating Akt. PHLPP2 overexpression 
increases apoptosis in cancer cell lines under low serum 
conditions; this effect is partially blocked by 
overexpressing an Akt mutant that is resistant to 
dephosphorylation by PHLPP. Conversely, siRNA-
mediated knockdown of PHLPP2 decreases basal and 
etoposide-stimulated apoptosis and increases cellular 
proliferation. 
PHLPP2 may also be involved in cAMP signaling to 
Akt. PHLPP2 binds adenylyl cyclase type 6 in cardiac 
myocytes, and treatments that raise cAMP levels 
decrease Akt HM phosphorylation, possibly through 
activation of PHLPP. 
Homology 
PHLPP is a highly conserved phosphatase; its earliest 
orthologue is the yeast protein CYR1. In addition t a 
PP2C phosphatase domain, a leucine-rich repeat, and a 
Ras association domain, CYR1 contains an adenylate 
cyclase domain near its C terminus. Though 
invertebrates have only one PHLPP gene, most 
vertebrates have genes for both PHLPP1 and PHLPP2. 
Mutations 
Somatic 
A common single nucleotide polymorphism (SNP) in 
the PP2C phosphatase domain of PHLPP2 may be 
involved in breast cancer progression. This SNP, a T-
>C nucleotide change at base pair position 3047, results 
in a Leu->Ser amino acid change at position 1016 in 
the PHLPP2 protein. Heterozygosity at this position is 
present in approximately 30% of the population, 
although Ser/Ser homozygosity has not yet been 
observed. 
The L1016S variant of PHLPP2 may be involved in 
breast cancer. Although most breast cancer cell lines 
are homozygous for the Leucine allele, some are 
homozygous for the Serine allele. In addition, the 
normal breast cell line Hs578Bst is heterozygous 
(Leu/Ser) at position 1016, while its pair-matched 
tumor cell line Hs578t has only the Serine allele, 
suggesting that the gene has undergone loss of 
heterozygosity in this tumor. Similar results were 
obtained upon comparing normal and tumor tissues 
from breast cancer patients who are heterozygous at 
position 1016. High-grade breast tumors from some of 
these patients exhibited loss of the Leucine allele, but 
no tumors exhibited loss of the Serine allele. Further 
characterization of the L1016S mutant has revealed that 
its phosphatase activity (as measured by activity toward 
Akt) and its ability to promote apoptosis are defective. 
Moreover, siRNA-mediated knockdown of PHLPP2 in 
Ser/Ser breast cancer cell lines has no effect on Akt 
phosphorylation or PKCalpha levels, while knocking 
down PHLPP2 in cell lines with at least one Leucine 
allele increases Akt phosphorylation and PKCalpha 
levels. All in all, the data indicate that the version of 
PHLPP2 with Serine at position 1016 is less functional  
towards Akt and PKC than the wildtype version, and  
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that loss of the wildtype allele in heterozygous 
(Leu/Ser) breast cancer patients may be involved in the 




16q22.3, the chromosomal locus containing PHLPP2, 
commonly undergoes loss of heterozygosity in breast 
and ovarian cancers, Wilms tumors, prostate cancer and 
hepatocellular carcinomas. 
Oncogenesis 
siRNA-mediated reduction of PHLPP2 in breast cancer 
cell lines results in decreased apoptosis and increased 
proliferation, suggesting that PHLPP2 may act as a 
tumor suppressor. In addition, wildtype PHLPP2 may 
be lost in breast tumors with a less-functional PHLP2 
(PHLPP2 L1016S; see "Mutations" section), resulting 




Overexpression of PHLPP1 or PHLPP2 in the human 
colon cancer cell lines HCT-116 and HT29 causes 
decreased expression of PKC and decreased 
phosphorylation of Akt. Cells overexpressing PHLPP 
exhibit decreased proliferation and were less able to 
induce tumors in nude mice. Conversely, DLD1 cells, 
which express high levels of PHLPP, respond to 
PHLPP1 or PHLPP2 knockdown with increased Akt 
phosphorylation, PKC stability, and proliferation. 
Chronic myelogenous leukemia 
Oncogenesis 
PHLPP mRNA levels may be decreased in chronic 
myelogenous leukemia (CML). Bcr-Abl, the fusion 
protein responsible for CML, downregulates PHLPP1 
and PHLPP2 mRNA levels; decreasing PHLPP levels 
interferes with the efficacy of Bcr-Abl inihibitors, 
including Gleevec, in CML cell lines. 
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